Comparative performance of human papillomavirus DNA testing using novel sample collection methods

Journal of Clinical Microbiology

Volumn 49, Issue 12, 2011, Pages 4185-4189

  Gage, Julia C ^a   Partridge, Edward E ^b   Rausa, Alfio ^c   Gravitt, Patti E ^d   Wacholder, Sholom ^a   Schiffman, Mark ^a   Scarinci, Isabel ^b   Castle, Philip E ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c MISSISSIPPI STATE DEPARTMENT OF HEALTH   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e American Society for Clinical Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADULT; AGED; ARTICLE; CANCER SCREENING; CONTROLLED STUDY; CYTODIAGNOSIS; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; FEMALE; GENOTYPE; HEALTH CARE PERSONNEL; HUMAN; INTERMETHOD COMPARISON; LIQUID BASED CYTOLOGY; MAJOR CLINICAL STUDY; MCNEMAR TEST; MEDICALLY UNDERSERVED; NONHUMAN; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SELF EXAMINATION; SENSITIVITY AND SPECIFICITY; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VIRUS DETECTION; VIRUS LOAD; WART VIRUS;

ADULT; AGED; CERVIX UTERI; CYTOLOGICAL TECHNIQUES; EARLY DETECTION OF CANCER; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; SELF-EXAMINATION; SPECIMEN HANDLING; VAGINA; VIROLOGY;

EID: 82455174869     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.01254-11     Document Type: Article

References (33)

1. Barbee, L., et al. 2010. Assessing the acceptability of self-sampling for HPV among Haitian immigrant women: CBPR in action. Cancer Causes Control 21:421-431.
2. Bastani, R., K. R. Yabroff, R. E. Myers, and B. Glenn. 2004. Interventions to improve follow-up of abnormal findings in cancer screening. Cancer 101: 1188-1200. (Pubitemid 39100413)
3. Belinson, J. L., et al. 2010. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal, and vaginal self-collected specimens: implications for vaginal self-collection. Int. J. Cancer 127:1151-1157.
4. Benard, V. B., H. W. Lawson, C. R. Eheman, C. Anderson, and W. Helsel. 2005. Adherence to guidelines for follow-up of low-grade cytologic abnormalities among medically underserved women. Obstet. Gynecol. 105:1323-1328. (Pubitemid 40734264)
5. Bulkmans, N. W., et al. 2007. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370: 1764-1772.
6. Castle, P. E., et al. 2011. Comparative community outreach to increase cervical cancer screening in the Mississippi Delta. Prev. Med. 152:452-455.
7. Castle, P. E., et al. 2007. Mouthwash as a low-cost and safe specimen transport medium for human papillomavirus DNA testing of cervicovaginal specimens. Cancer Epidemiol. Biomarkers Prev. 16:840-843. (Pubitemid 46650592)
8. Castle, P. E., et al. 2008. Human papillomavirus genotype specificity of hybrid capture 2. J. Clin. Microbiol. 46:2595-2604.
9. Datta, S. D., et al. 2008. Human papillomavirus infection and cervical cytology in women screened for cervical cancer in the United States, 2003-2005. Ann. Intern. Med. 148:493-500. (Pubitemid 351665417)
10. Du, P., et al. 2010. The roles of social domains, behavioral risk, health care resources, and chlamydia in spatial clusters of US cervical cancer mortality: not all the clusters are the same. Cancer Causes Control 21:1669-1683.
11. Dzuba, I. G., et al. 2002. The acceptability of self-collected samples for HPV testing versus the pap test as alternatives in cervical cancer screening. J. Womens Health Gender Based Med. 11:265-275.
12. Eggleston, K. S., A. L. Coker, K. J. Luchok, and T. E. Meyer. 2007. Adherence to recommendations for follow-up to abnormal Pap tests. Obstet. Gynecol. 109:1332-1341. (Pubitemid 46869872)
13. Freeman, H. P., and B. K. Wingrove. 2005. Excess cervical cancer mortality: a marker for low access to health care in poor communities. NIH pub. no. 05-5282. National Cancer Institute, Center to Reduce Cancer Health Disparities, Rockville, MD.
14. Giorgi Rossi, P., et al. 2011. The effect of self-sampled HPV testing on participation to cervical cancer screening in Italy: a randomised controlled trial (ISRCTN96071600). Br. J. Cancer 104:248-254.
15. Gok, M., et al. 2011. Experience with high-risk human papillomavirus testing on vaginal brush-based self-samples of non-attendees of the cervical screening program. Int. J. Cancer 129:517-527.
16. Gravitt, P. E., J. L. Belinson, J. Salmeron, and K. V. Shah. Looking ahead: a case for HPV testing of self-sampled vaginal specimens as a cervical cancer screening strategy. Int. J. Cancer, in press.
17. Gravitt, P. E., M. Schiffman, D. Solomon, C. M. Wheeler, and P. E. Castle. 2008. A comparison of linear array and hybrid capture 2 for detection of carcinogenic human papillomavirus and cervical precancer in ASCUS-LSIL triage study. Cancer Epidemiol. Biomarkers Prev. 17:1248-1254.
18. Jemal, A., et al. 2006. Cancer statistics, 2006. CA Cancer J. Clin. 56:106-130.
19. Knesel, B. W., J. C. Dry, C. Wald-Scott, and A. Aftab. 2005. Preliminary evaluation of a cervical self-sampling device with liquid-based cytology and multiparameter molecular testing. J. Reprod. Med. 50:256-260. (Pubitemid 40563419)
20. Mayrand, M. H., et al. 2007. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357:1579-1588.
21. Nanda, K., et al. 2000. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132:810-819. (Pubitemid 30317797)
22. Naucler, P., et al. 2007. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357:1589-1597. (Pubitemid 47598401)
23. Parfit, M. 1993. And what words shall describe the Mississippi, great father of rivers? Smithsonian 36:36.
24. Petignat, P., et al. 2007. Are self-collected samples comparable to physician-collected cervical specimens for human papillomavirus DNA testing? A systematic review and meta-analysis. Gynecol. Oncol. 105:530-535. (Pubitemid 46590347)
25. Qiagen. 2004. Hybrid Capture 2 High-Risk HPV DNA test package insert. Qiagen Corp., Gaithersburg, MD.
26. Roche Molecular Diagnostics. 2008. The Amplicor human papillomavirus test, package insert. Roche, Alameda, CA.
27. Roche Molecular Systems. 2006. Linear Array HPV genotyping test package insert. Roche Molecular Systems, Pleasanton, CA.
28. Ronco, G., et al. 2010. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 11:249-257.
29. Sandri, M. T., et al. 2006. Comparison of the Digene HC2 assay and the Roche Amplicor human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44:2141-2146. (Pubitemid 43902166)
30. Stevens, M. P., et al. 2007. Comparison of the Digene Hybrid Capture 2 assay and Roche Amplicor and Linear Array human papillomavirus (HPV) tests in detecting high-risk HPV genotypes in specimens from women with previous abnormal Pap smear results. J. Clin. Microbiol. 45:2130-2137. (Pubitemid 47203782)
31. Wentzensen, N., P. E. Gravitt, D. Solomon, C. M. Wheeler, and P. E. Castle. 2009. A study of Amplicor human papillomavirus DNA detection in the atypical squamous cells of undetermined significance-low-grade squamous intraepithelial lesion triage study. Cancer Epidemiol. Biomarkers Prev. 18: 1341-1349.
32. Wright, T. C., Jr., L. Denny, L. Kuhn, A. Pollack, and A. Lorincz. 2000. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA 283:81-86. (Pubitemid 30038387)
33. Wright, T. C., Jr., et al. 2007. 2006 consensus guidelines for the management of women with abnormal cervical screening tests. J. Lower Genital Tract Dis. 11:201-222.